Source Paper
Todd W. Vanderah, Luis R. Gardell, Shannon E. Burgess, Mohab Ibrahim, Ahmet Dogrul et al.
Journal of Neuroscience • 2000
The nonopioid actions of spinal dynorphin may promote aspects of abnormal pain after nerve injury. Mechanistic similarities have been suggested between opioid tolerance and neuropathic pain. Here, the hypothesis that spinal dynorphin might mediate effects of sustained spinal opioids was explored. Possible abnormal pain and spinal antinociceptive tolerance were evaluated after intrathecal administration of [D-Ala(2), N-Me-Phe(4), Gly-ol(5)]enkephalin (DAMGO), an opioid mu agonist. Rats infused with DAMGO, but not saline, demonstrated tactile allodynia and thermal hyperalgesia of the hindpaws (during the DAMGO infusion) and a decrease in antinociceptive potency and efficacy of spinal opioids (tolerance), signs also characteristic of nerve injury. Spinal DAMGO elicited an increase in lumbar dynorphin content and a decrease in the mu receptor immunoreactivity in the spinal dorsal horn, signs also seen in the postnerve-injury state. Intrathecal administration of dynorphin A(1-17) antiserum blocked tactile allodynia and reversed thermal hyperalgesia to above baseline levels (i.e., antinociception). Spinal dynorphin antiserum, but not control serum, also reestablished the antinociceptive potency and efficacy of spinal morphine. Neither dynorphin antiserum nor control serum administration altered baseline non-noxious or noxious thresholds or affected the intrathecal morphine antinociceptive response in saline-infused rats. These data suggest that spinal dynorphin promotes abnormal pain and acts to reduce the antinociceptive efficacy of spinal opioids (i.e., tolerance). The data also identify a possible mechanism for previously unexplained clinical observations and offer a novel approach for the development of strategies that could improve the long-term use of opioids for pain.
Objective: Evaluate dynorphin A(1-17) antiserum effects on tactile allodynia, thermal hyperalgesia, and morphine antinociceptive potency in DAMGO-infused rats to determine if spinal dynorphin mediates abnormal pain and opioid tolerance
This is a Dynorphin Antiserum Administration and Pain Reversal protocol using rat as the model organism. The procedure involves 14 procedural steps, 1 equipment items, 5 materials. Extracted from a 2000 paper published in Journal of Neuroscience.
Model and subjects
rat • Not specified • unknown • Not specified • Not specified
Study window
Estimated timing pending
Core workflow
Establish baseline pain thresholds • Intrathecal DAMGO infusion • Assess tactile allodynia
Primary readouts
Key equipment and reagents
Verified items
0
Direct vendor links
0
Use this page as an execution guide, then fall back to the source paper whenever you need exact exclusions, dosing details, or assay-specific caveats.
Confirm first
Use the page like this
Start here. The step list is optimized for running the experiment, with direct vendor links available inline when you need to source a cited item.
Measure baseline non-noxious and noxious thresholds in rats prior to any infusions
Note: Baseline measurements needed for comparison with treatment groups
“Neither dynorphin antiserum nor control serum administration altered baseline non-noxious or noxious thresholds”
Administer DAMGO intrathecally to induce abnormal pain and opioid tolerance
Note: DAMGO-infused rats develop tactile allodynia and thermal hyperalgesia
“Rats infused with DAMGO, but not saline, demonstrated tactile allodynia and thermal hyperalgesia of the hindpaws (during the DAMGO infusion)”
Measure tactile allodynia in hindpaws during DAMGO infusion
Note: Tactile allodynia is a sign of abnormal pain induced by DAMGO
“Rats infused with DAMGO, but not saline, demonstrated tactile allodynia and thermal hyperalgesia of the hindpaws”
Measure thermal hyperalgesia in hindpaws during DAMGO infusion
Note: Thermal hyperalgesia is a sign of abnormal pain induced by DAMGO
“Rats infused with DAMGO, but not saline, demonstrated tactile allodynia and thermal hyperalgesia of the hindpaws (during the DAMGO infusion)”
Quantify lumbar dynorphin content in spinal dorsal horn following DAMGO infusion
Note: DAMGO elicits an increase in lumbar dynorphin content
“Spinal DAMGO elicited an increase in lumbar dynorphin content and a decrease in the µ receptor immunoreactivity in the spinal dorsal horn”
Assess µ receptor immunoreactivity in spinal dorsal horn following DAMGO infusion
Note: DAMGO causes a decrease in µ receptor immunoreactivity
“Spinal DAMGO elicited an increase in lumbar dynorphin content and a decrease in the µ receptor immunoreactivity in the spinal dorsal horn”
Evaluate the antinociceptive potency and efficacy of spinal morphine in DAMGO-infused rats
Note: DAMGO-infused rats show decreased antinociceptive potency and efficacy of spinal opioids (tolerance)
“a decrease in antinociceptive potency and efficacy of spinal opioids (tolerance), signs also characteristic of nerve injury”
Administer dynorphin A(1-17) antiserum intrathecally to block dynorphin effects
Note: Antiserum treatment is applied to DAMGO-infused rats
“Intrathecal administration of dynorphin A(1–17) antiserum blocked tactile allodynia and reversed thermal hyperalgesia to above baseline levels”
Measure tactile allodynia following dynorphin antiserum administration
Note: Dynorphin antiserum blocks tactile allodynia induced by DAMGO
“Intrathecal administration of dynorphin A(1–17) antiserum blocked tactile allodynia and reversed thermal hyperalgesia to above baseline levels”
Measure thermal hyperalgesia following dynorphin antiserum administration
Note: Dynorphin antiserum reverses thermal hyperalgesia to above baseline levels (antinociception)
“Intrathecal administration of dynorphin A(1–17) antiserum blocked tactile allodynia and reversed thermal hyperalgesia to above baseline levels (i.e., antinociception)”
Evaluate the antinociceptive potency and efficacy of spinal morphine following dynorphin antiserum administration
Note: Dynorphin antiserum reestablishes morphine antinociceptive potency and efficacy
“Spinal dynorphin antiserum, but not control serum, also reestablished the antinociceptive potency and efficacy of spinal morphine”
Administer control serum intrathecally as a control comparison
Note: Control serum does not affect pain thresholds or morphine response in saline-infused rats
“Neither dynorphin antiserum nor control serum administration altered baseline non-noxious or noxious thresholds or affected the intrathecal morphine antinociceptive response in saline-infused rats”
Measure non-noxious and noxious thresholds in saline-infused control rats
Note: Saline-infused rats serve as controls and do not develop abnormal pain
“Rats infused with DAMGO, but not saline, demonstrated tactile allodynia and thermal hyperalgesia of the hindpaws”
Evaluate intrathecal morphine antinociceptive response in saline-infused rats
Note: Saline-infused rats maintain normal morphine antinociceptive response
“Neither dynorphin antiserum nor control serum administration altered baseline non-noxious or noxious thresholds or affected the intrathecal morphine antinociceptive response in saline-infused rats”
This section explains what the experiment is doing, which readouts matter, what the data artifacts usually look like, and how the analysis should flow from raw capture to reported result.
Evaluate dynorphin A(1-17) antiserum effects on tactile allodynia, thermal hyperalgesia, and morphine antinociceptive potency in DAMGO-infused rats to determine if spinal dynorphin mediates abnormal pain and opioid tolerance
Objective
Evaluate dynorphin A(1-17) antiserum effects on tactile allodynia, thermal hyperalgesia, and morphine antinociceptive potency in DAMGO-infused rats to determine if spinal dynorphin mediates abnormal pain and opioid tolerance
Subjects
From paperrat • Not specified • unknown • Not specified • Not specified
Cohort notes
From paperRats infused with DAMGO or saline as control groups
Establish baseline pain thresholds (Not specified)
Intrathecal DAMGO infusion (Not specified)
Assess tactile allodynia (Not specified)
Assess thermal hyperalgesia (Not specified)
Tactile allodynia in hindpaws
From paperNot specified in the provided text
Artifact type
Endpoint measurements summarized by group or timepoint
Comparison focus
Compare endpoint magnitude between groups, timepoints, or both
Thermal hyperalgesia in hindpaws
From paperNot specified in the provided text
Artifact type
Endpoint measurements summarized by group or timepoint
Comparison focus
Compare endpoint magnitude between groups, timepoints, or both
Antinociceptive potency of spinal morphine
From paperNot specified in the provided text
Artifact type
Endpoint measurements summarized by group or timepoint
Comparison focus
Compare endpoint magnitude between groups, timepoints, or both
Antinociceptive efficacy of spinal morphine
From paperNot specified in the provided text
Artifact type
Endpoint measurements summarized by group or timepoint
Comparison focus
Compare endpoint magnitude between groups, timepoints, or both
Tactile allodynia in hindpaws
From paperRaw artifact
Per-sample or per-animal endpoint measurements collected during the experiment
Processed artifact
Structured table with cleaned measurements ready for comparison
Final reported form
Summary statistics and between-group or across-timepoint comparisons
Thermal hyperalgesia in hindpaws
From paperRaw artifact
Per-sample or per-animal endpoint measurements collected during the experiment
Processed artifact
Structured table with cleaned measurements ready for comparison
Final reported form
Summary statistics and between-group or across-timepoint comparisons
Antinociceptive potency of spinal morphine
From paperRaw artifact
Per-sample or per-animal endpoint measurements collected during the experiment
Processed artifact
Structured table with cleaned measurements ready for comparison
Final reported form
Summary statistics and between-group or across-timepoint comparisons
Antinociceptive efficacy of spinal morphine
From paperRaw artifact
Per-sample or per-animal endpoint measurements collected during the experiment
Processed artifact
Structured table with cleaned measurements ready for comparison
Final reported form
Summary statistics and between-group or across-timepoint comparisons
Acquisition
Collect raw experimental outputs with enough metadata to preserve sample identity, condition, and timing.
Preprocessing / cleaning
Not specified in the provided text
Scoring or quantification
Quantify the primary readouts for this experiment: Tactile allodynia in hindpaws; Thermal hyperalgesia in hindpaws; Antinociceptive potency of spinal morphine; Antinociceptive efficacy of spinal morphine.
Statistical comparison
Statistical method not yet structured for this page.
Reporting output
Report representative outputs alongside summary comparisons for Tactile allodynia in hindpaws, Thermal hyperalgesia in hindpaws, Antinociceptive potency of spinal morphine, Antinociceptive efficacy of spinal morphine.
Source links and direct wording from the methods section for validation and deeper review.
Citation
Todd W. Vanderah et al. (2000). Dynorphin Promotes Abnormal Pain and Spinal Opioid Antinociceptive Tolerance. Journal of Neuroscience
“”
“”
“”
“”
Direct vendor pages are linked from the protocol above. This section stays focused on the full comparison view and the prep checklist.
Gather these items before starting the experiment. Check off items as you prepare.
Not specified • Not specified • Not specified • Not specified
Not specified • Not specified • Not specified • Not specified
Not specified • Not specified • Not specified • Not specified
Not specified • Not specified • Not specified • Not specified
Not specified • Not specified • Not specified • Not specified
Not specified • Not specified • Not specified • Not specified
Use this section as the page quality checkpoint. It keeps section navigation, evidence access, readiness, and verification meaning in one place.
Current status surfaces were computed from experiment data updated Feb 28, 2026.
Source access
Jump back into the original paper or the methods evidence section when you need exact wording, exclusions, or method-specific caveats.
This protocol has structured steps plus evidence quotes, and is ready for canonical sync.
Steps
14
Evidence Quotes
20
Protocol Items
6
Linked Products
0
Canonical Sync
Pending
What this means
The completeness score reflects how much structured protocol data is present: steps, methods evidence, listed materials, linked products, and paper provenance.
Computed from the current experiment record updated Feb 28, 2026.
Canonical Sync shows whether a ConductGraph-backed protocol is available for this experiment route right now. It is a sync-status signal, not a claim that every downstream vendor link or step detail is perfect.
Steps
14
Evidence
20
Specific Products
0/0
Canonical Sync
Pending
What this score means
The verification score reflects evidence coverage, subject detail, paper provenance, step depth, and whether linked products resolve to specific item pages instead of generic searches.
Computed from the current experiment record updated Feb 28, 2026.
A page can have structured steps and still need review when evidence is thin, product links are generic, or canonical protocol coverage is still pending.
What still needs work